NCT02100085View on ClinicalTrials.gov

Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation

UnknownOBSERVATIONAL
Enrollment

9

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Cervical Intraepithelial Neoplasia 3
Interventions
BIOLOGICAL

GX-188E

In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.

Trial Locations (1)

Unknown

Cheil General Hospital & Women's Healthcare Center, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT02100085 - Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation | Biotech Hunter | Biotech Hunter